TCGA-GD-A76B-01A-11R-A32O-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.490
- ALLOGRAFT_REJECTION+0.410
- INTERFERON_GAMMA_RESPONSE+0.340
- BILE_ACID_METABOLISM+0.320
- KRAS_SIGNALING_DN+0.300
- INTERFERON_ALPHA_RESPONSE+0.280
- IL6_JAK_STAT3_SIGNALING+0.270
- INFLAMMATORY_RESPONSE+0.250
- TNFA_SIGNALING_VIA_NFKB+0.210
- FATTY_ACID_METABOLISM+0.200
Top 10 suppressed
- G2M_CHECKPOINT-0.490
- E2F_TARGETS-0.480
- MITOTIC_SPINDLE-0.480
- TGF_BETA_SIGNALING-0.480
- MYC_TARGETS_V1-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- PROTEIN_SECRETION-0.380
- MYC_TARGETS_V2-0.370
- UV_RESPONSE_DN-0.350
- ANGIOGENESIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-91-A4BD-01A-11R-A24H-07 | — | cohortA1 | 0.893 |
| 2 | TCGA-GV-A3QK-01B-11R-A23N-07 | — | — | 0.865 |
| 3 | MNG1161 | — | — | 0.854 |
| 4 | TCGA-50-6597-01A-11R-1858-07 | — | cohortA1 | 0.844 |
| 5 | ERR2598268 | fetal | fetal | 0.841 |
| 6 | SRR2778078 | — | — | 0.839 |
| 7 | SRR13780258 | — | cohortMD2 | 0.835 |
| 8 | SJEPD040_D.RNA-Seq | EPN | Supratentorial EPN | 0.832 |
| 9 | 28f73ee0-f218-4884-81c6-e6b4ba2fdccd | — | — | 0.827 |
| 10 | 855f0a82-04de-485d-9613-5ccf08074069 | — | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.490 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |